EUVIMEDEUVIMED entdecken
Open Access

Flucloxacillin worsens while imipenem–cilastatin protects against vancomycin‐induced kidney injury in a translational rat model

Gwendolyn M Pais, Sylwia Marianski, Kimberly Valdez, Renz Paulo Melicor, Jiajun Liu, Roxane Rohani, Jack Chang, Steven Y C Tong, Joshua S Davis, Marc H Scheetz iD

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Gwendolyn M Pais und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Midwestern University-Downers Grove Campus, Downers Grove, Illinois, USA. Hauptthemen laut MEDLINE: Vancomycin, Floxacillin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Vancomycin is one of the most common clinical antibiotics, yet acute kidney injury is a major limiting factor. Common combinations of antibiotics with vancomycin have been reported to worsen and improve vancomycin‐induced kidney injury. We aimed to study the impact of flucloxacillin and imipenem–cilastatin on kidney injury when combined with vancomycin in our translational rat model. Experimental Approach Male Sprague–Dawley rats received allometrically scaled (1) vancomycin, (2) flucloxacillin, (3) vancomycin + flucloxacillin, (4) vancomycin + imipenem–cilastatin or (5) saline for 4 days. Kidney injury was evaluated via drug accumulation and urinary biomarkers including urinary output, kidney injury molecule‐1 (KIM‐1), clusterin and osteopontin. Relationships between vancomycin accumulation in the kidney and urinary kidney injury biomarkers were explored. Key Results Urinary output increased every study day for vancomycin + flucloxacillin, but after the first dose only in the vancomycin group. In the vancomycin + flucloxacillin group, urinary KIM‐1 increased on all days compared with vancomycin. In the vancomycin + imipenem–cilastatin group, urinary KIM‐1 was decreased on Days 1 and 2 compared with vancomycin. Similar trends were observed for clusterin. More vancomycin accumulated in the kidney with vancomycin + flucloxacillin compared with vancomycin and vancomycin + imipenem–cilastatin. The accumulation of vancomycin in the kidney tissue correlated with increasing urinary KIM‐1. Conclusions and Implications Vancomycin + flucloxacillin caused more kidney injury compared with vancomycin alone and vancomycin + imipenem–cilastatin in a translational rat model. The combination of vancomycin + imipenem–cilastatin was nephroprotective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinFloxacillinRatsMaleAnimalsCilastatin, Imipenem Drug CombinationClusterinRats, Sprague-DawleyAnti-Bacterial AgentsKidneyBiomarkersDrug Combinations

Stichwörter der Autor:innen

acute kidney injurybiomarkersdrug-induced kidney injuryflucloxacillinimipenem-cilastatinnephrotoxicitypreclinicalrodentvancomycin

Substanzen

Cilastatin, Imipenem Drug CombinationVancomycinFloxacillinClusterinAnti-Bacterial AgentsBiomarkersDrug Combinations

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Midwestern University-Downers Grove Campus, Downers Grove, Illinois, USA.
  • Pharmacometrics Center of Excellence, Midwestern University-Downers Grove Campus, Downers Grove, Illinois, USA.
  • Midwestern University College of Pharmacy, Downers Grove, Illinois, USA.
  • Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
  • Victorian Infectious Diseases Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

ORCID-Profile: Marc H Scheetz

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Pais, G. M., Marianski, S., Valdez, K., Melicor, R. P., Liu, J., Rohani, R., Chang, J., Tong, S. Y. C., Davis, J. S., & Scheetz, M. H. (2024). Flucloxacillin worsens while imipenem–cilastatin protects against vancomycin‐induced kidney injury in a translational rat model. British Journal of Pharmacology. https://doi.org/10.1111/bph.16234

Vancouver

Pais GM, Marianski S, Valdez K, Melicor RP, Liu J, Rohani R, et al. Flucloxacillin worsens while imipenem–cilastatin protects against vancomycin‐induced kidney injury in a translational rat model. British Journal of Pharmacology. 2024. doi:10.1111/bph.16234

BibTeX
@article{Pais2024,
  author = {Pais, Gwendolyn M and Marianski, Sylwia and Valdez, Kimberly and Melicor, Renz Paulo and Liu, Jiajun and Rohani, Roxane and Chang, Jack and Tong, Steven Y C and Davis, Joshua S and Scheetz, Marc H},
  title = {Flucloxacillin worsens while imipenem–cilastatin protects against vancomycin‐induced kidney injury in a translational rat model},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16234}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche